{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Niraparib+Treatment&page=2", "query": { "intervention": "Niraparib Treatment", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 80, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Niraparib+Treatment&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Niraparib+Treatment&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T23:30:29.966Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04972110", "title": "Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor, Adult" ], "interventions": [ { "name": "RP-3500 (camonsertib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repare Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2021-07-21", "completion_date": "2024-11-13", "has_results": true, "last_update_posted_date": "2025-10-30", "last_synced_at": "2026-10-03T23:30:29.966Z", "location_count": 13, "location_summary": "Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04972110" }, { "nct_id": "NCT06388733", "title": "A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma", "GBM", "Brain Neoplasms, Adult, Malignant", "Brain Tumor" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ivy Brain Tumor Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2024-06-19", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-03T23:30:29.966Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Guilford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06388733" }, { "nct_id": "NCT04221061", "title": "18F-FluorThanatrace (PET/CT) in Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "18F-FluorThanatrace", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 3, "start_date": "2020-02-20", "completion_date": "2024-06-10", "has_results": false, "last_update_posted_date": "2024-06-17", "last_synced_at": "2026-10-03T23:30:29.966Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04221061" }, { "nct_id": "NCT06915025", "title": "Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epithelial Ovarian Cancer", "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Imunon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 500, "start_date": "2025-07-09", "completion_date": "2032-10-31", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-03T23:30:29.966Z", "location_count": 9, "location_summary": "Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06915025" }, { "nct_id": "NCT03586661", "title": "Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Deleterious BRCA1 Gene Mutation", "Deleterious BRCA2 Gene Mutation", "Endometrial Adenocarcinoma", "High Grade Ovarian Serous Adenocarcinoma", "Platinum-Resistant Ovarian Carcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Progressive Disease", "Recurrent Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Copanlisib", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 31, "start_date": "2019-04-29", "completion_date": "2026-06-16", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-03T23:30:29.966Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03586661" }, { "nct_id": "NCT03221400", "title": "PEN-866 in Patients With Advanced Solid Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma", "Endometrial Adenocarcinoma", "Neoplasms", "Squamous Cell Carcinoma of the Anus", "Adenocarcinoma of the Pancreas", "Advanced Cancer", "Solid Tumor", "Solid Carcinoma", "Squamous Cell Carcinoma of the Cervix", "Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Vulva", "Squamous Cell Carcinoma of the Penis", "Gastric Cancer", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Small-cell Lung Cancer", "Small Cell Lung Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "PEN-866 Sodium", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tarveda Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2017-08-29", "completion_date": "2023-06", "has_results": false, "last_update_posted_date": "2022-02-17", "last_synced_at": "2026-10-03T23:30:29.966Z", "location_count": 16, "location_summary": "Springdale, Arkansas • Denver, Colorado • Fort Myers, Florida + 13 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03221400" }, { "nct_id": "NCT03891615", "title": "Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-06-06", "completion_date": "2024-11-07", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-03T23:30:29.966Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03891615" }, { "nct_id": "NCT04641247", "title": "A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms", "Breast Neoplasms" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2021-04-16", "completion_date": "2026-12-28", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-03T23:30:29.966Z", "location_count": 13, "location_summary": "Tucson, Arizona • Encinitas, California • Los Angeles, California + 10 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04641247" }, { "nct_id": "NCT04992013", "title": "Niraparib in Tumors Metastatic to the CNS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer", "Central Nervous System Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-04-05", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-03T23:30:29.966Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04992013" }, { "nct_id": "NCT04915755", "title": "Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-06-28", "completion_date": "2025-12-31", "has_results": true, "last_update_posted_date": "2025-07-16", "last_synced_at": "2026-10-03T23:30:29.966Z", "location_count": 24, "location_summary": "Burbank, California • Duarte, California • Palo Alto, California + 20 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04915755" } ] }